Gold Explorer Advancing Two Canadian Properties, Benefiting from New Brunswick Protection Status of Mining Claims

By The Gold Report

Source: Streetwise Reports   04/08/2020

X-Terra Resources has the funding to simultaneously explore two of its properties.

X-Terra Resources Inc.’s (XTT:TSX; XTR:FSE) gold exploration properties are in Canada, the Grog and Northwest project in New Brunswick and Troilus East in Quebec.

The company recently completed an inaugural, 1,904-meter drill program at the Grog and Northwest properties, where it has an option to earn a 70% interest.

New Brunswick is an especially good place to be exploring right now, as the provincial government has placed all mineral claims under protection status, “to ensure continuity of mineral claims during this time” of extreme uncertainty. This means that work requirements for the 2020 exploration season are waived for active claims and all active claims are extended for one year. X-Terra is one of only a handful of companies exploring specifically for gold in New Brunswick.

“This is a bold step and demonstrates the outstanding leadership and support the government has taken to ensure stability for individuals and companies like X-Terra, that have been working and will continue exploring in the province, once the Covid-19 pandemic situation begins to improve,” Michael Ferreira, president and CEO of X-Terra, stated.

In addition, “New Brunswick, with its vast network of forestry roads, provides so much access that it allows the company to put almost all of the money into the ground. The chances of success are higher because there are more funds being spent on actual exploration versus camp costs, logistics costs, helicopter costs, etc. That’s one on the reasons we’re really fond of New Brunswick, the infrastructure there, and, of course, its gold potential,” Ferreira told Streetwise Reports.

Having drilled 16 holes in five targets at Grog and Northwest, the company is awaiting assay results for 11 of the holes, all of which come from the Grog property. X-Terra noted that the program has already exceeded its expectations, “as all geological targets have revealed very encouraging visual indicators of significant alteration and mineralization in different contexts related with the MacKenzie Gulch Fault.”

The first drill results published were from the Northwest property, which is actually located south of Grog. “In an area of the property 2 km west of Rim and 3 km north of Dome and Bonanza, trenching revealed grades up to 4.5 g/t gold. We noticed in the trenches there were more parallel veins, confirming a stockwork existed, and there was more alteration than we had observed elsewhere. So the decision was made to drill under our trenches,” Ferreira said.

Assay results for the first two holes at the Northwest property were released on February 18. “The numerous anomalous results in gold, including 6.93 g/t Au over 0.5 meter in NWST-20-003 and 1.2 g/t Au over 1 meter in NWST-20-002 prove that the system is gold bearing,” the company stated.

“Hitting gold values in these first holes is big step and really encouraging considering that the initial gold discovery was generated by fortuitous roadside prospecting and pre-existing till samples completed by X-Terra. The extension of the till survey in that direction warrants additional sampling, which will ultimately reduce the initial 500 meters spacing between samples, and will without a doubt, define more accurate exploration targets that will eventually be followed up with additional drilling,” Ferreira noted.

As for the Grog property, Ferreira said that “when our senior geologist went out to the property for the first round of due diligence and verification, he observed some important key alteration components, which are very closely associated with epithermal and porphyry deposits. All the work that we’ve been doing and the discoveries that we’ve made on Grog have enabled us to design an intelligent drill program to carry out tests over four different targets spanning 3.7 km within a gold-bearing corridor. More importantly, the 11 drill holes pending all originate within a 1.6 km gold bearing corridor that is extremely favorable, from Grog to Bellevue South. Our primary objective is to see if we can connect that entire system all together.”

The company also plans to be active at its Troilus East property in north-central Quebec very shortly. The project is adjacent to Troilus Gold Corp.’s (TLG:TSX; CHXMF:OTC) property, which currently has a mineral resource of 4.71 million ounces of gold equivalent Indicated and 1.76 million ounces gold equivalent Inferred. Troilus recently completed at 6,000-meter drill program and raised just over $12 million. X-Terra’s Troilus East is located less than 2 km from the former open-pit mine that saw historical production of 2 million ounces of gold and 70,000 tons of copper.

Troilus East, which is 100% owned by X-Terra and is royalty-free, is made up of 182 mining claims covering around 93 sq km.

The area overall has recently been a beehive of activity. “We have seen Troilus Gold and others staking claims in and around the entire Frotet Evans Greenstone Belt and to the south. The area is getting a lot of attention and a lot of money is being spent to acquire land in this area,” Ferreira said.

“This summer we have the budget of $400,000 up to $600,000 to go and put some boots on the ground at Troilus East, to complement the work that’s already been done in New Brunswick,” Ferreira noted.

X-Terra is actively exploring both its Quebec and New Brunswick projects. “As we wait for the remaining New Brunswick drill results to come in, we are completing some additional compilation to better understand the projects to come up with new targets and new exploration approaches in order to increase our chances at a discovery,” Ferreira explained.

“Our exploration strategy has remained unchanged and we were lucky to complete our drill program before the Covid-19 outbreak,” Ferreira noted.

X-Terra has 61.7 million shares outstanding, 85,783,102 million fully diluted. Current strategic investors include Caisse de Depot, Sidex, SDBJ, FTQ and Desjardins Securities.

The company recently closed a non-brokered private placement of 3 million units at CA$0.08 per unit, for gross proceeds of $240,000. Each unit consists of one common share and a warrant to purchase one additional common share at CA$0.13 until March 25, 2023. The company noted that the funds will be used for exploration at the New Brunswick and Quebec properties and for working capital purposes.

X-Terra has garnered the attention of industry observers. Michael Kryton of Equity IR wrote on October 15, 2019, “X-Terra Resources Inc. is proving to be one of the sector’s most persistent gold diggers. The Quebec-based junior gold exploration company just announced results from its stripping and trenching activities at the Grog and Northwest properties in the Restigouche County in New Brunswick. The new discovery, referred to as the ‘Bellevue showing,’ revealed a gold value of 2.24 g/t Au.”

“For a company that has been in the sector for just five years, X-Terra Resources has been consistently producing results and growth. For investors, these are the hallmarks of a good thing. Good as gold,” Kryton concluded.

Technical analyst Clive Maund charted X-Terra and on February 24 wrote, “The price and its moving averages are tightly bunched together, a circumstance that frequently precedes the start of a major bull market, and an advance from here will quickly lead to moving averages swinging into bullish alignment.” He rated the stock “an immediate strong speculative buy.”

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Patrice Fusillo compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: X-Terra Resources. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with X-Terra Resources. Please click here for more information.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of X-Terra Resources, a company mentioned in this article.

Additional disclosures:

Disclosures from Equity IR
This web site and our newsletter are services of Equity IR, a media and advertising firm that is from time-to-time compensated by the companies profiled on this web site’s or in our newsletter’s. When compensated in shares, readers should be aware that it is our policy to liquidate all shares immediately. The liquidation of our stock may have a negative impact on the securities of the company liquidated, including decreased market value and/or dilution of the company’s securities All direct and third party compensation received has been disclosed on our newsletter and on this disclaimer in accordance with section 17(b) of the Securities Act of 1933. Equity IR.

www.equityir.com website, and all of its financial websites and the information provided are through its investor relations website www.investedgroup.com. Equity IR. newsletters are electronic publications, and is for informational purposes only. Equity IR. covers both client and non-client issuers. Equity IR. provides information on selected public companies. All companies profiled and featured on this website or on Equity IR. emails pay cash, unrestricted stock or restricted stock to Equity IR as compensation for the electronic dissemination of the company’s information and our comments about the company. Section 17(b) of the Securities Act of 1933 requires that Equity IR. fully discloses the type compensation (i.e. cash, unrestricted stock, restricted stock, and restricted stock with registration rights, stock options, stock warrants, or other type compensation) and the specific amount of the compensation our company receives or will receive, directly or indirectly, from an issuer, underwriter, or dealer. No information contained in our website, e-mail communications or our publications should be considered as a solicitation to purchase or sell the securities of the profiled companies. Equity IR or any of its employees are not registered investment advisers or a registered securities broker dealers in any jurisdictions. We do not undertake or represent to make investment recommendations or to give advice pertaining to the purchase or sale of the securities mentioned in our web site, e-mail communications or publications.

CliveMaund.com
Clive Maund does not own shares of X-Terra Resources, and neither he nor his company has a financial relationship with the company.

( Companies Mentioned: XTT:TSX; XTR:FSE,
)

Brazil Project to Drive Streaming Firm’s Near-Term Growth

By The Gold Report

Source: Streetwise Reports   04/08/2020

The technical update on the asset, which Wheaton Precious Metals owns a production stream on, is explored in a CIBC report.

In a March 31 research note, CIBC analyst Cosmos Chiu reported that Wheaton Precious Metals Corp. (WPM:TSX; WPM:NYSE) released an updated technical report for the Salobo copper-gold project in Brazil. “The update reiterates the Salobo gold stream’s position as Wheaton’s cornerstone asset and a key driver for the company’s near-term production growth outlook,” he commented. Wheaton holds a 75% gold stream there.

Chiu pointed out the changes between the previous technical report in 2017 and the recently updated one. The new report updated the mine plan, which now outlines an increase in average annual gold production through 2024 of about 330,000 ounces versus 300,000 ounces previously.

The plan also calls for annual throughput expansion at the Salobo III mill to 36 from 24 million tons and the processing of lower-grade material to feed the mill. However, Chiu indicated, “Additional upside exists if Salobo proceeds with a higher cut-off grade strategy, which would bring higher grade material forward in the production plan.”

Given the mill expansion, which is expected to be finished in 2022, Salobo’s open-pit operations now are expected to end sooner, in 2044 versus 2045, and the duration of stockpiling will decrease, to 7 years from 12.

The updated technical report also reflected that 292 million tons of reserves at the mine were reclassified as Probable from Proven “due to back analysis of drill spacing data,” wrote Chiu.

Once the new processing line is completed at Salobo, Wheaton is obligated to make an expansion payment, the amount of which will depend on the completion date, the expansion size and the copper cutoff grade. Wheaton now estimates the payment will be around $570 million, but, Chiu noted, if the mine plan calling for the higher cutoff grade gets implemented, it would be more like $670 million.

Finally, CIBC expects that during 2020 Wheaton will consider additional asset acquisitions, particularly since the recent weakness in base metals prices creates opportunities for buying byproduct streams.

CIBC has an Outperformer rating and a US$36 per share target price on Wheaton, whose stock is trading now at about US$29.39.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

Disclosures from CIBC, Wheaton Precious Metals Corp., Earnings Update, March 31, 2020

Analyst Certification:
Each CIBC World Markets Corp./Inc. research analyst named on the front page of this research report, or at the beginning of any subsection hereof, hereby certifies that (i) the recommendations and opinions expressed herein accurately reflect such research analyst’s personal views about the company and securities that are the subject of this report and all other companies and securities mentioned in this report that are covered by such research analyst and (ii) no part of the research analyst’s compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by such research analyst in this report.

Potential Conflicts of Interest:
Equity research analysts employed by CIBC World Markets Corp./Inc. are compensated from revenues generated by various CIBC World Markets Corp./Inc. businesses, including the CIBC World Markets Investment Banking Department. Research analysts do not receive compensation based upon revenues from specific investment banking transactions. CIBC World Markets Corp./Inc. generally prohibits any research analyst and any member of his or her household from executing trades in the securities of a company that such research analyst covers. Additionally, CIBC World Markets Corp./Inc. generally prohibits any research analyst from serving as an officer, director or advisory board member of a company that such analyst covers.

In addition to 1% ownership positions in covered companies that are required to be specifically disclosed in this report, CIBC World Markets Corp./Inc. may have a long position of less than 1% or a short position or deal as principal in the securities discussed herein, related securities or in options, futures or other derivative instruments based thereon.

Recipients of this report are advised that any or all of the foregoing arrangements, as well as more specific disclosures set forth below, may at times give rise to potential conflicts of interest.

Important Disclosure Footnotes for Wheaton Precious Metals Corp. (WPM.N)

• 2g CIBC World Markets Inc. expects to receive or intends to seek compensation for investment banking services from
these companies in the next 3 months: Wheaton Precious Metals Corp.

For important disclosure footnotes for companies mentioned in this report that are covered by CIBC World Markets Inc., click
here: Disclaimers & Disclosures.

( Companies Mentioned: WPM:TSX; WPM:NYSE,
)

Novavax Announces Its First-in-Human Coronavirus Vaccine Trial Will Begin in Mid-May

By The Life Science Report

Source: Streetwise Reports   04/08/2020

Shares of Novavax traded 20% higher setting a new 52-week high price after the company reported that it has accelerated initiation of a Phase 1 clinical trial for its coronavirus vaccine candidate NVX-CoV2373. The study will commence in mid-May with preliminary results expected in July 2020.

Late-stage biotechnology company Novavax Inc. (NVAX:NASDAQ), which is focused on developing next-generation vaccines to address infectious diseases, today announced it has identified a coronavirus vaccine prefusion protein candidate named NVX-CoV2373 utilizing the firm’s proprietary nanoparticle technology and will initiate a first-in-human trial in mid-May. The firm additionally advised that “its proprietary Matrix-M™ adjuvant will be incorporated with NVX-CoV2373 in order to enhance immune responses and stimulate high levels of neutralizing antibodies.”

The company stated that in prior animal models measuring spike protein-specific antibodies, NVX-CoV2373 was shown to be highly immunogenic. The firm explained that “high levels of spike protein-specific antibodies with ACE-2 human receptor binding domain blocking activity and SARS-CoV-2 wild-type virus neutralizing antibodies were observed after a single immunization.”

The company’s President of Research and Development Gregory Glenn, M.D., commented, “Our scientists identified an ideal vaccine candidate selected from a number of constructs and, in partnership with Dr. Matthew Frieman, demonstrated that NVX-CoV2373 produces high levels of neutralizing antibodies against SARS-CoV-2 in animal studies…In addition, we have worked closely with our colleagues at Emergent BioSolutions to transfer our production technology that allows the manufacture of GMP vaccine for clinical trials. With preliminary CEPI funding, these heroic efforts, combined with the candidate’s excellent early results, put us in position to have preliminary human data in July.”

Matthew Frieman, Ph.D., associate professor at the University of Maryland School of Medicine, added, “We validated that NVX-CoV2373 generates high titer neutralizing antibodies against live SARS-CoV-2 virus…This is strong evidence that the vaccine created by Novavax has the potential to be highly immunogenic in humans which could lead to protection from COVID-19 and helping to control the spread of this disease.”

The company mentioned that “the NVX-CoV2373 clinical development plan combines a Phase 1/Phase 2 approach to allow rapid advancement during the current coronavirus pandemic.” The Phase 1 clinical trial will study 130 healthy adults and evaluate dosage levels and the number of vaccinations.

Earlier this year in March, the firm reported that it formed an agreement with Emergent BioSolutions to provide contract development and manufacturing services and to supply Novavax with GMP vaccine product for clinical trial use. The company indicated that this relationship offers the potential to leverage Emergent’s rapid deployment abilities and expertise that will allow Novavax capacity to produce vaccine product at scale. The firm also noted that it received $4 million in funding from the Coalition for Epidemic Preparedness Innovations in support of its vaccine discovery efforts.

Novavax’s President and CEO Stanley C. Erck remarked, “Because of the tireless efforts and commitment of the Novavax team and our collaborators, we are preparing to initiate the NVX-CoV2373 Phase 1 trial in mid-May, weeks ahead of schedule…This progress demonstrates the ability of our recombinant nanoparticle technology to rapidly create vaccine candidates for emerging viruses like SARS-CoV-2. In addition, the performance of NVX-CoV2373 in multiple preclinical studies and testing gives us increased confidence in its potential to protect against COVID-19 disease.”

The firm noted that the newest coronavirus strain, SARS-CoV-2, first appeared in China in late 2019 prior to spreading worldwide and that the COVID-19 disease continues to cause severe pneumonia-like symptoms in many infected individuals. The company further explained that coronaviruses spread from animals to humans and include diseases such as MERS and SARS in addition to COVID-19.

Novavax is a late-stage biotechnology company headquartered in Gaithersburg, Md., with additional facilities located in Rockville, Md., and Uppsala, Sweden. The firm is focused on improving global health through discovery, development and commercialization of novel vaccines to prevent serious infectious diseases. The company’s product pipeline includes clinical vaccine candidates for respiratory syncytial virus, seasonal influenza and Ebola virus and other infectious diseases.

Novavax has a market capitalization of around $767.8 million with approximately 51.53 million shares outstanding and a short interest of about 10.40%. NVAX shares opened 15% higher today at $17.15 (+$2.25, +15.109%) over yesterday’s $14.90 closing price and reached a new 52-week high price this morning of $18.25. The stock has traded today between $16.30 and $18.25 per share and is currently trading at $17.56 (+$2.66, +17.85%).

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: NVAX:NASDAQ,
)

Biopharma’s Technology Could Render Drug Suitable for COVID-19 Treatment

By The Life Science Report

Source: Streetwise Reports   04/08/2020

How this could be achieved using the proprietary platform of TFF Pharmaceuticals and why it could work are discussed in a ROTH Capital Partners report.

In an April 7 research note, ROTH Capital Partners analyst Jonathan Aschoff discussed the potential of applying TFF Pharmaceuticals Inc.’s (TFFP:NASDAQ) thin film freezing (TFF) technology to an existing drug to create a possible COVID-19 therapy.

The hypothesis is that the biopharma’s TFF platform could be used on niclosamide, turning it into an inhalable version, thereby improving its pharmacokinetics because it has low absorption and oral bioavailability at around 10%, Aschoff explained.

An essential drug according to the World Health Organization, niclosamide is an anthelminthic (used to treat tapeworm infestations), has several mechanisms of action and has broad antiviral activity. “Niclosamide can inhibit SARS-associated coronavirus replication and totally abolish viral antigen synthesis,” according to a recent publication (doi:10.1021/acsinfecdis.0c00052) reviewed by Aschoff, he noted.

Currently, researchers at the University of Texas at Austin (UT), which is affiliated with Texas-based TFF Pharmaceuticals through various research agreements, are working on such an approach.

UT researchers are using novel drug delivery formulation technologies to increase the absorption of niclosamide, thereby optimizing it for both oral and inhaled administration “that could best treat COVID-19 symptoms in severely affected patients by delivering the drug directly to the most problematic site of infection,” described Aschoff. Using TFF Pharmaceutical’s thin film freezing technology, the UT team is turning niclosamide into “micronized crystalline dry powder formulations and an amorphous brittle matrix powder.”

Aschoff pointed out, “We favor existing drugs that have a known adverse event profile from both clinical and commercial use, and to this end TFF Pharmaceuticals is performing an exhaustive review of U.S. Food and Drug Administration approved drugs that could be repurposed to treat COVID-19 patients or used prophylactically.”

ROTH has a Buy rating and a $15 per share target price on TFF Pharmaceuticals, whose current share price is about $4.96.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Disclosures from ROTH Capital Partners, TFF Pharmaceuticals, Company Note, April 7, 2020

Regulation Analyst Certification (“Reg AC”): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

ROTH makes a market in shares of TFF Pharmaceuticals, Inc. and as such, buys and sells from customers on a principal basis.

Shares of TFF Pharmaceuticals, Inc. may be subject to the Securities and Exchange Commission’s Penny Stock Rules, which may set forth sales practice requirements for certain low-priced securities.

ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months.

( Companies Mentioned: TFFP:NASDAQ,
)

Tullow Oil, Cenovus Energy, Arconic & UTX lead Weekly Top Gainers/Losers

By IFCMarkets

Top Gainers – The World Market

World oil prices rose by about 30% over the week.Investors are expecting a reduction in the oil output of OPEC+ member countries. Against this background, shares of oil and gas companies showed the greatest increase. As often happens, a correction may occur after the announcement of real volumes of oil production decline.There is even an exchange saying about this: Buy the rumor, sell the fact.

1. Tullow Oil PLC – a British oil and gas company.

2. Cenovus Energy Inc – a Canadian oil and gas company.

market sentiment ratio long short positions

 Top Losers – The World Market

1. Arconic Inc. – an American aluminum producer (former Alcoa).

2. United Technologies Corporation – an American company manufacturing military aerospace and civil construction equipment.

market sentiment ratio long short positions

 Top Gainers – Foreign Exchange Market (Forex)

1. AUDJPY, AUDCHF – the growth of these charts means the strengthening of the Australian dollar against the Japanese yen and the Swiss franc.

2. USDTRY, USDZAR – the growth of these charts means the weakening of the Turkish lira and the South African rand to the US dollar.

market sentiment ratio long short positions

 Top Losers – Foreign Exchange Market (Forex)

1. EURRUB, USDRUB – the fall of these charts means the strengthening of the Russian ruble against the euro and the US dollar.

2. EURAUD, EURNZD – the fall of these charts means the strengthening of the Australian and New Zealand dollars against the euro.

market sentiment ratio long short positions

Market Analysis provided by IFCMarkets

Note:
This overview has an informative and tutorial character and is published for free. All the data, included in the overview, are received from public sources, recognized as more or less reliable. Moreover, there is no guarantee that the indicated information is full and precise. Overviews are not updated. The whole information in each overview, including opinion, indicators, charts and anything else, is provided only for familiarization purposes and is not financial advice or а recommendation. The whole text and its any part, as well as the charts cannot be considered as an offer to make a deal with any asset. IFC Markets and its employees under any circumstances are not liable for any action taken by someone else during or after reading the overview.

EURUSD Analysis: Smaller slowing of industrial output in France bullish for EURUSD

By IFCMarkets

Smaller slowing of industrial output in France bullish for EURUSD

Industrial production growth slowed in France less than expected in February: industrial output growth slowed to 0.9% over month in February, after 1.1% rise in January, when no change was forecast. This is bullish for EURUSD.

IndicatorVALUESignal
RSINeutral
MACDSell
Donchian ChannelBuy
MA(200)Buy
FractalsBuy
Parabolic SARBuy

 

Summary of technical analysis

OrderBuy
Buy stopAbove 1.0949
Stop lossBelow 1.0920

Market Analysis provided by IFCMarkets

Will People Keep Investing In China After COVID-19?

By Orbex

Last year, China recorded the highest level of foreign direct investment in its history. This came despite the trade war with the US.

China was the second-largest recipient of FDI after the United States. And about a quarter of it was directed to manufacturing, while 15% of it was into high tech and computing.

The breakdown shows how China has been moving from being a manufacturing hub towards higher added value products.

This isn’t a unique path, as a matter of fact. Japan went through a similar process after WWII, leading many observers to project that China would, in the future, be at least economically similar to Japan.

Investment in manufacturing was already starting to be superseded by other activities before the start of the new decade.

All your eggs in one basket

China had, for several years, realized that it couldn’t – and didn’t want to – remain the world’s manufacturing center.

The trade war just made the country’s leaders redouble efforts already underway to turn the economy’s focus to domestic demand. The COVID-19 outbreak exposed a distinct flaw in concentrating so much manufacturing in one country.

Apparently, China had been aware of this problem for a long time. In fact, it had been looking to address it.

On the one hand, China has been seeking to secure diversity in its raw material sourcing. On the other, it has also been working to become independent from foreign demand and world economic swings.

Meanwhile, the rest of the world continued business as usual.

It’s not a change, just an acceleration of an already existing pattern

As China shut down manufacturing to stop the spread of COVID-19, analysts were suddenly aware of potential supply problems. This was a slight economic headache, that could be solved by China beating the virus and reopening the economy.

But when the virus spread around the world, and everyone was desperately seeking vital medical supplies… the lack of domestic production became an acute issue.

Many have pointed to China offering masks, ventilators and other equipment as a goodwill gesture attempting to gain diplomatic presence. But there is another motive: if too many countries can’t get vital supplies because they are all made in China, they will be a lot more interested in “bringing home” certain industries.

It’s a little too fast

In the long run, perhaps China would be happy to focus on more tech industries. However, they aren’t in a position to do that just yet. China still needs foreign investment to support its massive economic growth.

With the world economy practically shut for an extended period, there will be little “extra” money for investments in the short term. The next six months might simply be a period of taking stock and trying to return the world economy to some semblance of normal.

To be sure, China will play a role in that.

But, with virtually every company in the world cutting capital expenditure, new investment into China is going to be on hold for a while. Given the “reset”, companies will likely reassess their capital programs and strategies.

While expansion into China would have seemed like the logical next step in 2019 that would happen by inertia, come the end of 2020, that might not be the case.

By Orbex

 

Gold Rally To Test 2020 Highs

By Orbex

Gold

Gold prices continued their recent rally this week with the yellow metal heading back up towards the 2020 highs. The recovery in asset markets continues to support the upside in gold. Gold has now almost totally reversed the sell-off seen over March in response to the outbreak of the COVID-19 virus.

Over the last two weeks, risk appetite has stabilized. Breaking from the typical correlation seen, gold prices have been trading higher in tandem with equities markets.

The main catalyst behind the drive higher in asset markets this week was the latest announcement from the Fed. In yet a further unscheduled announcement, the US central announced a $2.3 trillion loan program. In a statement issued on Thursday, Fed Chairman Powell said:

“Our country’s highest priority must be to address this public health crisis, providing care for the ill and limiting the further spread of the virus”.

Powell continued, saying:

“The Fed’s role is to provide as much relief and stability as we can during this period of constrained economic activity, and our actions today will help ensure that the eventual recovery is as vigorous as possible.”

This latest announcement comes on the back of the Fed recently announcing its decision to start running limitless QE. Gold prices are now well supported in the midst of this massive injection of liquidity. It looks set to keep inflation expectations anchored firmly lower over the rest of the year.

Gold Market Approaching Key Resistance

The yellow metal prices continue to hold above the bullish channel which has been acting as support on recent retests. While above here, focus remains on a break of the 2020 highs at 1700. Next with a focus on a test of the mid-2012 highs (1750.67) next. However, bearish divergence in the RSI indicator warrants attention. Unless we move above the 1700 level, we could see some short term selling from the level.

Silver

This week, silver prices have been equally well supported. The ongoing rally in equities helping lift silver prices. Given its frequent industrial usage, silver prices tend to be impacted by movements in key industrial indices. With US industrial benchmarks continuing higher this week, supported by the broader recovery in asset markets, silver prices have room to continue higher here

Silver prices Trading Within Rising Wedge Pattern

Silver prices continue to trade higher with the rally above the 14.3722 level continuing to gather pace. However, technical analysts will note that the recovery is framed by a rising wedge pattern. This pattern is currently raising risks of a reversal lower. The 16.3502 level will now be a key pivot point for silver. The level will either provide the platform for a further recovery or the stalling point for the current recovery.

By Orbex

 

Forex Technical Analysis & Forecast 10.04.2020

Article By RoboForex.com

EURUSD, “Euro vs US Dollar”

After breaking 1.0888 upwards and then reaching 1.0930, EURUSD has almost completed the ascending wave. Today, the pair is expected to form a new consolidation range near the highs and expand it up to 1.0960. After that, the instrument may break 1.0920 and then resume moving inside the downtrend with the first target at 1.0888.

EURUSD
Risk Warning: the result of previous trading operations do not guarantee the same results in the future

GBPUSD, “Great Britain Pound vs US Dollar”

GBPUSD is moving at the top of the ascending wave. Possibly, the pair may expand the range up to 1.2555 and then start another decline with the first target at 1.2140.

GBPUSD
Risk Warning: the result of previous trading operations do not guarantee the same results in the future

USDCHF, “US Dollar vs Swiss Franc”

After breaking 0.9696 downwards and reaching 0.9650, USDCHF has almost finished this descending wave; right now, it is moving near the lows. Today, the pair may form a new consolidation range there and expand it down to 0.9635. After that, the instrument may form one more ascending structure with the first target at 0.9696.

USDCHF
Risk Warning: the result of previous trading operations do not guarantee the same results in the future

USDJPY, “US Dollar vs Japanese Yen”

USDJPY is consolidating around 108.67. Possibly, today the pair may fall towards 108.22 and then grow to return to 108.67. Later, the market may form a new descending structure towards 108.92 and then start another growth with the target at 108.67.

USDJPY
Risk Warning: the result of previous trading operations do not guarantee the same results in the future

AUDUSD, “Australian Dollar vs US Dollar”

AUDUSD has expanded the range up to 0.6320. Possibly, today the pair may fall to reach 0.6200 and then start a new growth towards 0.6260. If the price breaks 0.6200, the instrument may continue trading downwards with the first target at 0.6000.

AUDUSD
Risk Warning: the result of previous trading operations do not guarantee the same results in the future

USDRUB, “US Dollar vs Russian Ruble”

After breaking 74.50 downwards and reaching 72.70, USDRUB is expected to continue falling. According to the main scenario, today the price may test 74.70 from below. If the price rebounds from this level and updates the lows, the market may continue trading inside the downtrend with the target at 71.50. Otherwise, the instrument may start a new correction towards 77.00 and then resume trading downwards with the above-mentioned target.

USDRUB
Risk Warning: the result of previous trading operations do not guarantee the same results in the future

USDCAD, “US Dollar vs Canadian Dollar”

USDCAD is trading to break 1.3950 downwards. Possibly, the pair may reach the short-term target at 1.3822. After that, the instrument may grow to test 1.3950 from below and then continue trading downwards with the target at 1.3800.

USDCAD
Risk Warning: the result of previous trading operations do not guarantee the same results in the future

XAUUSD, “Gold vs US Dollar”

After breaking 1660.00 and forming an upside continuation pattern, Gold has reached 1682.00; right now, it is consolidating near the highs. The main scenario implies that the pair may fall to break 1674.00. The first downside target is at 1660.00.

GOLD
Risk Warning: the result of previous trading operations do not guarantee the same results in the future

BRENT

Brent has completed the ascending wave towards 35.45; right now, it is falling to reach 29.50. Later, the market may grow towards 32.32, thus forming a new consolidation range between these two levels.

BRENT
Risk Warning: the result of previous trading operations do not guarantee the same results in the future

BTCUSD, “Bitcoin vs US Dollar”

BTCUSD is consolidating around 7200.00. Today, the pair may fall towards 7000.00 and then grow to return to 7200.00. If later the price breaks this range to the downside, the market may correct to reach 6600.00; if to the upside – form one more ascending structure with the target at 7550.00.

BITCOIN

Article By RoboForex.com

Attention!
Forecasts presented in this section only reflect the author’s private opinion and should not be considered as guidance for trading. RoboForex LP bears no responsibility for trading results based on trading recommendations described in these analytical reviews.

Oil Prices Volatile On OPEC Speculation

By Orbex

WTI Crude oil prices are trading volatile on Thursday. Price action rose to intraday highs of 28.32 while setting a low of 25.10.

The volatility comes amid speculation that Saudi Arabia and Russia are agreeing on cutting oil output by 20 million barrels.

Price action remains within the range of 28.00 and 22.00.

We expect this ranging price action to continue until there is a strong breakout from one of the levels.

By Orbex